Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,229 recruiting studies in this area right now.
By phase
- Not applicable3,142
- Phase 21,065
- Phase 1822
- Phase 1/Phase 2446
- Phase 3423
- Phase 4237
- Phase 2/Phase 394
Top conditions
- Multiple Sclerosis341
- Multiple Myeloma332
- Asthma194
- Lymphoma182
- Rheumatoid Arthritis142
- Type 1 Diabetes133
- Atopic Dermatitis128
- Systemic Lupus Erythematosus125
- Acute Lymphoblastic Leukemia123
- HIV Infections116
- Chronic Lymphocytic Leukemia100
- Autoimmune Diseases81
- Follicular Lymphoma74
- Diabetes Mellitus, Type 169
- Hodgkin Lymphoma67
- Rheumatoid Arthritis (RA)65
- Leukemia64
- Acute Myeloid Leukemia62
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China91
- National Institute of Allergy and Infectious Diseases (NIAID)90
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris70
- M.D. Anderson Cancer Center63
- Novartis Pharmaceuticals63
- AstraZeneca57
- City of Hope Medical Center47
- Mayo Clinic46
- Memorial Sloan Kettering Cancer Center45
Where studies are running
- California492
- Maryland196
- Alabama176
- Florida143
- Arizona141
- New York123
- Massachusetts119
- Texas117
- Illinois82
- Colorado77
Recruiting studies6,229 total
- NCT04561557RecruitingEarly Phase 1
Cell therapy for relapsing nervous system autoimmune diseases
This early-phase trial tests CT103A “CAR-T” cell therapy to treat certain relapsing or treatment-resistant autoimmune diseases that affect the nervous system. It aims to see whether the cells are safe and may help reduce disease activity when standard treatments haven’t controlled symptoms.
Wuhan, HubeiAges 18–75 - NCT04565483RecruitingPhase 4
Test a blood-test signature to predict benralizumab benefit
This trial studies whether a specific “signature” from asthma tests can predict who will respond to benralizumab (a severe asthma biologic). If you qualify, the researchers will compare your test results to how well benralizumab controls your asthma and prevents flare-ups.
Aix-en-ProvenceAges 18–75 - NCT04570423RecruitingPhase 2
Eflapegrastim safety study for children and teens on chemo
This trial studies how safe eflapegrastim is in pediatric patients with certain solid tumors or lymphomas who are starting chemotherapy that lowers white blood cells. It also looks at how the medicine behaves in the body to help reduce the risk of dangerous infections.
Valhalla, New YorkAges 1 month–17 years - NCT04571658Recruiting
NEPTUNE Match study linking you to possible kidney research trials
This study is an add-on process that uses information from the NEPTUNE kidney study to see whether you might be able to join other kidney research trials. It may help connect eligible people with appropriate new treatment studies when they become available.
Atlanta, GeorgiaAges 1–80 - NCT04573140RecruitingPhase 1
RNA vaccine study for newly diagnosed adult and pediatric brain tumors
This Phase 1 trial studies an “RNA-lipid particle” vaccine given after surgery for certain newly diagnosed brain cancers (glioblastoma in adults, high-grade glioma in children/teens). The goal is to see whether the vaccine is safe and can train the immune system to fight the tumor.
Washington D.C., District of ColumbiaAges 4 years+ - NCT04573673Recruiting
Tapping the shin nerve to help bladder control in MS
This study tests a noninvasive nerve stimulation applied to the lower leg to improve bladder emptying problems in people with multiple sclerosis. It may help reduce bladder dysfunction while you keep using clean intermittent self-catheterization.
LilleAges 18–65 - NCT04575883Recruiting
Bike interval training for teens with repaired heart defects
This study tests a structured “interval” bike exercise program to see if it’s safe and helpful for teens with certain repaired congenital heart conditions. It may help improve fitness while closely monitoring heart symptoms during training.
Edmonton, AlbertaAges 10–18 - NCT04577313Recruiting
Study to improve HIV medicine adherence reminders
This study looks at a way to help people take their HIV medicines as prescribed. It focuses on people who are HIV-positive and not currently taking their treatment consistently.
Storrs, ConnecticutAges 18 years+ - NCT04578171Recruiting
Mepolizumab for severe asthma flare-ups after treatment
This trial studies whether mepolizumab can reduce ongoing or returning asthma flare-ups in people with severe asthma. If you have severe asthma that still keeps flaring, this may help by targeting a specific inflammation pathway involved in some asthma cases.
Québec, QuebecAges 18–90 - NCT04586478RecruitingPhase 2
CNCT19 cell therapy for relapsed or resistant non-Hodgkin lymphoma
This Phase 2 trial tests whether an injected cell therapy called CNCT19 can treat non-Hodgkin lymphoma that has come back or did not respond to prior treatment. It may help by targeting specific lymphoma cells, but you must meet several safety and medical eligibility checks.
Beijing, Beijing MunicipalityAges 18–75 - NCT04589299RecruitingPhase 4
Subcutaneous immune globulin for newly diagnosed CIDP
This study tests whether giving immune globulin under the skin (SCIG) can help people with newly diagnosed CIDP. It may help improve muscle strength and nerve symptoms while avoiding the need for earlier IVIG/SCIG treatment.
AalborgAges 18 years+ - NCT04603196Recruiting
Study sleep apnea in adults with multiple sclerosis
This study looks at how often sleep apnea happens in people who have multiple sclerosis, and how it affects daily life and health. You may be invited to participate if you’re an adult with a confirmed multiple sclerosis diagnosis and can consent to the study.
Boston, MassachusettsAges 18 years+ - NCT04604041Recruiting
Study early warning signs in relapsing-remitting multiple sclerosis
This study looks at “subclinical markers,” meaning early or hidden body changes that may show how relapsing-remitting multiple sclerosis (MS) is doing even when symptoms seem mild. It may help researchers find better ways to monitor MS and detect changes sooner.
SplitAges 18–65 - NCT04603872RecruitingEarly Phase 1
CAR-T plus dasatinib for hard-to-treat B-cell cancers
This early study tests a cancer-fighting treatment that uses CAR-T cells together with dasatinib for people whose B-cell cancers have come back or did not respond. It aims to improve control of the cancer in cases that are often resistant to standard treatment.
Hangzhou, ZhejiangAges 18–70 - NCT04604990Recruiting
National lupus patient study for adults in Saudi Arabia
This study follows adults with systemic lupus erythematosus (lupus) to better understand the condition over time. If you meet common lupus diagnosis standards, you may be able to join—there’s no limit on when you were diagnosed.
Riyadh, Central ProvinceAges 19 years+ - NCT04607174Recruiting
Test knee muscle activation in people with nerve or movement disorders
This study checks how well your knee muscles “turn on” during guided, controlled knee movements. It may help researchers understand movement problems and improve testing or therapies for neuromotor (nerve/movement) disorders.
Milan, MIAges 18–70 - NCT04615065Recruiting
Biobank study collecting emergency data for very sick patients
This study collects health and sometimes blood sample information from people arriving at the emergency department with high-risk or serious conditions. The goal is to build a large emergency “biobank” to help researchers better understand and improve urgent care.
GroningenAges 18 years+ - NCT04624490RecruitingPhase 1
Lung function MRI using a special gas in volunteers
This Phase 1 study tests a lung scan that uses a special gas and MRI to measure how well your lungs work. It includes healthy volunteers and people with lung disease to see how well the scan works and how safe it is.
Kansas City, KansasAges 3 years+ - NCT04629144RecruitingPhase 2
Belimumab for active cryoglobulinemia vasculitis after rituximab
This Phase 2 study tests belimumab (or a placebo) to see if it improves safety and disease control in adults with active cryoglobulinemia vasculitis. You may be eligible if you have had rituximab induction treatment shortly before joining, and your illness is still active.
BloisAges 18 years+ - NCT04629586Recruiting
T1D Exchange registry for people with type 1 diabetes
This trial registry collects information about people living with type 1 diabetes to help researchers better understand the condition. It may help by allowing future studies and improving how care is studied and planned.
Boston, MassachusettsAges Any age - NCT04634552RecruitingPhase 2
Talquetamab study for relapsed or refractory multiple myeloma
This trial studies talquetamab, a medicine given to treat multiple myeloma that has come back or did not respond to prior treatment. It may help shrink tumors and improve disease control, depending on how your myeloma measures and your health status.
Birmingham, AlabamaAges 18 years+ - NCT04635436Recruiting
Split-walking training for one-sided leg weakness when walking hurts
This trial tests whether a “split gait” walking training method can improve walking balance and how you move when you have one-sided leg problems and pain or limitations when walking. It may help reduce walking difficulties by training your stepping pattern safely.
Milan, MIAges 18–70 - NCT04634994RecruitingEarly Phase 1
Brain scans to measure synapses in multiple sclerosis
This early study uses special brain scans (PET and MRI) to measure “synapse density” (how many connection points brain cells have) in people with multiple sclerosis (MS). It may help researchers understand MS biology and improve future treatments.
Boston, MassachusettsAges 18–60 - NCT04639791Recruiting
Managing asthma in adults on GINA steps 4 to 5
This study looks at how well guideline-based asthma treatment works for adults with more severe asthma (GINA steps 4 and 5). It may help improve real-world care for people whose asthma needs stronger medications to stay controlled.
ShatinAges 18 years+
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,229 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,721 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.